SPRO vs TXT · P/E 9.6, rev $258.0K vs P/E 19, rev $7.52B
Spero Therapeutics Inc (SPRO) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported SPRO revenue for 2026-06-30 was $258.0K. Net income was -$16.8M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
SPRO currently screens at market cap $149.5M and trailing P/E 9.6. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the SPRO and TXT stock pages for the full models.
Not investment advice.